Citations

Clear

9 citation(s) found for "Rossi, Andrea".

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study
Yamshon, Samuel , Koff, Jean L. , Larson, Melissa C. , Kahl, Brad S. , Casulo, Carla , Lossos, Izidore S. , Haddadi, Sara , Stanchina, Michele , Chihara, Dai , Ayers, Amy , Khurana, Arushi , Nowakowski, Grzegorz S. , Reicks, Tanner W., Cohen, Jonathon B. , Martin, Peter , Li, Jia , Shewade, Ashwini, Batlevi, Connie Lee , Lo‐Rossi, Andrea, Fox, David , Masaquel, Anthony, Mun, Yong, Flowers, Christopher R. , Habermann, Thomas , Wang, Yucai , Khurana, Arushi , Nowakowski, Grzegorz S , Farooq, Umar , Link, Brian K , Cohen, Jonathon B , Li, Jia , Shewade, Ashwini , Batlevi, Connie L , Lo-Rossi, Andrea , Fox, David , Masaquel, Anthony , Cerhan, James R , Maurer, Matthew , Kahl, Brad S , Koff, Jean L , Chihara, Dai , Casulo, Carla , Larson, Melissa C , Habermann, Thomas M. , Wang, Yucai , Link, Brian K. , Cerhan, James R. , Maurer, Matthew J. , Nastoupil, Loretta J.

Mayo Clinic

American Journal of Hematology | February 7, 2025 | Volume: 100 | Issue: 4 | Pages: 606-615

10.1002/ajh.27630 | PMID 39918101 Get It

ABSTRACT Rituximab, gemcitabine, and oxaliplatin (R‐GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), but there are limited real‐world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high‐grade B cell lymphoma treated with R‐GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy ( n = 100), those utilizing R‐GemOx as a bridge to ASCT or CAR T ( n = 83), and those aged 70 and older ( n = 71). Overall response rates (ORRs) for all patients treated with R‐GemOx were 45% with a complete response (CR) rate of 29%. The median event‐free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R‐GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R‐GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R‐GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R‐GemOx in the rapidly evolving landscape of R/R DLBCL therapies.
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
Yamshon, Samuel , Casulo, Carla , Lossos, Izidore S. , Haddadi, Sara , Ayers, Amy , Khurana, Arushi , Nowakowski, Grzegorz S. , Reicks, Tanner W., Cohen, Jonathon B. , Martin, Peter , Li, Jia , Shewade, Ashwini, Batlevi, Connie Lee , Lo‐Rossi, Andrea, Fox, David J. , Masaquel, Anthony, Mun, Yong, Flowers, Christopher R. , Koff, Jean L. , Larson, Melissa C. , Kahl, Brad S. , Casulo, Carla , Stanchina, Michele , Chihara, Dai , Habermann, Thomas M. , Wang, Yucai , Farooq, Umar , Link, Brian K. , Cerhan, James R. , Maurer, Matthew J. , Nastoupil, Loretta J.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3093-3093

10.1182/blood-2024-208111 Get It

Background: Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly utilized chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), especially for patients ineligible for autologous stem cell transplant (ASCT) or chimeric antigen receptor T cell therapy (CAR T). R-GemOx is used as a comparator arm in several active phase III clinical trials for R/R DLBCL, including the POLARGO (polatuzumab vedotion and R-GemOx), STARGLO (glofitamab and GemOx), SUNMO (mosunetuzumab and polatuzumab vedotin), LOTIS-5 (loncastuximab tesirine and rituximab), and EPCORE DLBCL-1 (epcoritamab) studies. However, real-world data are limited to understand the patterns of use and outcomes of R-GemOx in the US. Methods: We developed a retrospective multicenter US cohort (known as LEO CReWE) of patients with R/R DLBCL and other aggressive B-cell lymphomas at the eight US academic centers participating in the LEO Cohort Study (NCT02736357). Patients first diagnosed with DLBCL (including transformed and high-grade B-cell lymphoma) from 2007 - 2022 who received second line (2L) or later therapy for R/R DLBCL with R-GemOx were included. Baseline characteristics, treatment, and follow-up data were abstracted by chart review. Index line of therapy was defined as the first receipt of R-GemOx therapy in the 2L or later setting. Intent for CAR T and/or ASCT was evaluated at each line of therapy based on medical records at the time of treatment initiation. Subgroup analyses were pre-planned in groups of special interest, including those treated with R-GemOx without intent for ASCT or CAR T, those treated as a bridge to CAR T, and those aged 70 and older. Results: 183 patients with R/R DLBCL treated with R-GemOx were included. At time of initiation of R-GemOx, median age was 68 years (range 21-88), with 71 patients (39%) aged 70+ and 18 (10%) aged 80+. Many patients had high risk features including 13% with high grade B-cell lymphoma and 56% with IPI 3 or greater. 21% had an ECOG performance status of 2 or greater. Patients received a median of 2 lines of therapy prior to the index line of R-GemOx (range 1-7). 52% of patients did not achieve a complete response (CR) to first-line therapy, and 20% relapsed <12 months from an initial CR. In all patients receiving R-GemOx, the overall response rate (ORR) was 45% (29% CR). At a median follow-up of 39 months, median EFS was 2.3 months (95% CI: 1.8-3.2), with 12-month EFS of 21% and a 24-month EFS of 15%. Median OS was 13.5 months (95% CI: 9.6-18.1), with a 12-month OS of 52% and a 24-month OS of 38%. In patients treated without intent for ASCT or CAR T, ORR was 33% (18% CR). Median EFS was 2.0 months (95% CI: 1.6-2.5) with 12- and 24-month EFS of 14% and 9%, respectively. Median OS was 9.5 months (95% CI: 6.6-16.1) with 12- and 24-month OS of 45% and 29%, respectively. In patients receiving R-GemOx as bridging to ASCT or CAR T, ORR was 57% (35% CR). 35% received CAR T and 14% received ASCT, while the remainder did not receive the intended therapy as part of this line. Median EFS was 3.6 months (95% CI: 1.8-5.2) with 12- and 24-month EFS of 28% and 25%, respectively. Median OS was 17.4 months (95% CI: 13.4-NR); 12- and 24-month OS were 61% and 50%, respectively. In patients aged 70+, ORR was 53% (33% CR). Median EFS was 2.3 months (95% CI: 1.6-5.2), with 12- and 24-month EFS of 20% and 18%, respectively. Median OS was 13.9 months (95% CI: 8.6-30.2); 12- and 24-month OS were 57% and 39%, respectively. Conclusion: This study represents the largest reported cohort of patients treated with R-GemOx in US academic centers to date. The ORR of 45% and CR rate of 29% CR, as well as median EFS and OS of 2.3 and 13.5 months, respectively, are consistent with findings from previous phase II studies; these results highlight that responses to R-GemOx are not durable and the vast majority of patients require additional therapy. This study demonstrates real-world evidence of the efficacy of R-GemOx in a large cohort of patients with R/R DLBCL from the US over a long period, including both transplant-eligible and -ineligible patients, and patients treated in the CAR T era. These data aid in providing a benchmark for active clinical trials in the rapidly evolving landscape of R/R DLBCL therapies and allow potential comparison to a real-world cohort of patients with a broad range of clinical characteristics.
Stress and Quality of Life of Parents of Children With POLR3-Related Leukodystrophy: A Cross-Sectional Pilot Study
Lentini, Laura , Toutounchi, Helia, Chapleau, Alexandra , Le, Adam , Fournier, Simon, Emari, Fatemeh, Flamini, Robert , Gentile, Ángela , Venkateswaran, Sunita, Keller, Stephanie , Renaud, Deborah L. , Pereira, Danilo de Assis , Chen, Xiaoru , Gentile, Angela , Pohl, Daniela , Renaud, Deborah , Rossi, Andrea , Bertini, Enrico , Nicita, Francesco , Rossignol, Elsa , Vanderver, Adeline , Bernard, Geneviève

Mayo Clinic

Journal of Child Neurology | October 21, 2024 | Volume: 40 | Issue: 1 | Pages: 26-38

10.1177/08830738241283171 | PMID 39429022 Get It

Background: RNA polymerase III (POLR3)-related leukodystrophy is a rare, neurodegenerative disorder characterized by hypomyelination, hypodontia, and hypogonadotropic hypogonadism. Despite the challenges of caring for a child with POLR3-related leukodystrophy, few studies have examined parents’ disease burden. We sought to investigate quality of life and stress levels amongst parents of children with POLR3-related leukodystrophy. Methods: 43 parents of 32 children completed questionnaires on demographics, stress, quality of life, coping mechanisms, and experience of injustice. Detailed clinical data was collected from all patients. Results: Mothers ( t[27] = –8.66, P < .001) and fathers (t[16] = –4.47, P < .001) had lower quality of life scores compared to the normative population, yet 80% of parents’ stress scores fell within the normal stress range. Parents’ experience of injustice scores were high (>60). Correlations were found between and within parents’ scores. Years since disease onset and certain life circumstances correlated to mothers’ quality of life scores; however, no correlation was found between modifiable factors and fathers’ quality of life scores. Helpful coping mechanisms included those that allowed parents to be involved in their child's life. Conclusions: This is the first study to assess stress and quality of life in this population. These results shed light on the importance of implementing services and social support to improve the well-being of parents.
Survival loss linked to guideline-based indications for degenerative mitral regurgitation surgery
Vancraeynest, David , Gerber, Bernhard, Benfari, Giovanni , Essayagh, Benjamin , Tribouilloy, Christophe , Ruşinaru, Dan, Ewe, See Hooi , investigators, MIDA (Mitral Regurgitation International Database), Antoine, Clémence , Malouf, Joseph F., Michelena, Hector, Guerra, Federico, Russo, Antonio Dello, Chow, Josie , Fan, Yiting , Keh, Yann Shan , Hamid, Nadira , Pin, Ding Zee, Trojette, Faouzi, Touati, Gilles, Rémadi, Jean Paul , Poulain, H, Ditaranto, Raffaello , Caponetti, Giuseppe, Savini, Carlo , Melfi, Rosetta, Meester, Christophe de, Khoury, Gébrine El , Gerber, Bernhard , Pasquet, Agnès, Collart, Frédéric , Avierinos, Jean Francois, Rossi, Andrea , Essayagh, Benjamin , Tribouilloy, Christophe , Bursi, Francesca , Biagini, Elena , Enriquez-Sarano, Maurice , Benfari, Giovanni , Pouleur, Anne–Catherine , Meester, Christophe de , Pasquet, Agnès , Michelena, Héctor I. , Grigioni, Francesco , Barbieri, Andréa , Bursi, Francesca , Aviérinos, Jean-François , Guerra, Federico , Yeo, Khung Keong , Lee, Alex Pui‐Wai , Vanoverschelde, Jean‐Louis , Enriquez‐Sarano, Maurice , investigators, MIDA (Mitral Regurgitation International Database), Michelena, Hector, Nkomo, Vuyisile T. , Guerra, Federico, Barbarossa, Alessandro , Russo, Antonio Dello, Wong, Randolph H.L. , Wan, Song , Caponetti, Giuseppe Angelo, Pacini, Davide , Chello, Massimo , Nusca, Annunziata , Ussia, Gian Paolo , Meester, Christophe de, Pasquet, Agnès, Théron, Alexis , Avierinos, Jean-Fançois, Mantovani, Francesca , Modena, Maria Grazia , Boriani, Giuseppe , Onorati, Francesco , Ribichini, Flavio Luciano

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | July 11, 2024 | Volume: 25 | Issue: 12 | Pages: 1703-1711

10.1093/ehjci/jeae176 | PMID 38996050 Get It

Abstract Aims Operating on patients with severe degenerative mitral regurgitation (DMR) is based on ACC/AHA or ESC/EACTS guidelines. Doubts persist on best surgical indications and their potential association with postoperative survival loss. We sought to investigate whether guideline-based indications lead to late postoperative survival loss in DMR patients. Methods and results We analysed outcome of 2833 patients from the Mitral Regurgitation International Database registry undergoing surgical correction of DMR. Patients were stratified by surgical indications: Class I trigger (symptoms, left ventricular end-systolic diameter ≥ 40 mm, or left ventricular ejection fraction &lt; 60%, n = 1677), isolated Class IIa trigger [atrial fibrillation (AF), pulmonary hypertension (PH), or left atrial diameter ≥ 55 mm, n = 568], or no trigger (n = 588). Postoperative survival was compared after matching for clinical differences. Restricted mean survival time (RMST) was analysed. During a median 8.5-year follow-up, 603 deaths occurred. Long-term postoperative survival was lower with Class I trigger than in Class IIa trigger and no trigger (71.4 ± 1.9, 84.3 ± 2.3, and 88.9 ± 1.9% at 10 years, P &lt; 0.001). Having at least one Class I criterion led to excess mortality (P &lt; 0.001), while several Class I criteria conferred additional death risk [hazard ratio (HR): 1.53, 95% confidence interval (CI): 1.42–1.66]. Isolated Class IIa triggers conferred an excess mortality risk vs. those without (HR: 1.46, 95% CI: 1.00–2.13, P = 0.05). Among these patients, isolated PH led to decreased postoperative survival vs. those without (83.7 ± 2.8% vs. 89.3 ± 1.6%, P = 0.011), with the same pattern observed for AF (81.8 ± 5.0% vs. 88.3 ± 1.5%, P = 0.023). According to RMST analysis, compare to those operated on without triggers, operating on Class I trigger patients led to 9.4-month survival loss (P &lt; 0.001) and operating on isolated Class IIa trigger patients displayed 4.9-month survival loss (P = 0.001) after 10 years. Conclusion Waiting for the onset of Class I or isolated Class IIa triggers before operating on DMR patients is associated with postoperative survival loss. These data encourage an early surgical strategy.
International Consensus Statement on the Radiological Screening of Contact Children in the Context of Suspected Child Physical Abuse
Mankad, Kshitij , Sidpra, Jai , Oates, Adam , Kan, Elaine , Agrawal, Nina, Kelly, Patrick J. , Zeitlin, Deborah, Carter, Jamieson, Debelle, Geoff , Berger, Rachel P. , Christian, Cindy W. , Lindberg, Daniel M. , Raissaki, Maria , Argyropoulou, Maria I. , Adamsbaum, C. , Cain, Timothy , Silvera, V. Michelle , Kemp, Alison , Choudhary, Arabinda K. , Offiah, Amaka C , Mirsky, David M. , Colleran, Gabrielle , Lucato, Leandro Tavares , Kilborn, Tracy , Teeuw, Arianne Hélène , Zeitlin, Deborah, Carter, Jamieson, Rijn, Rick Robert van , Rossi, Andrea

Mayo Clinic

JAMA Pediatrics | March 6, 2023 | Volume: 177 | Issue: 5 | Pages: 526

10.1001/jamapediatrics.2022.6184 | PMID 36877504 Get It

Importance Physical abuse is a common but preventable cause of long-term childhood morbidity and mortality. Despite the strong association between abuse in an index child and abuse in contact children, there is no guidance outlining how to screen the latter, significantly more vulnerable group, for abusive injuries. Consequently, the radiological assessment of contact children is often omitted, or variably performed, allowing occult injuries to go undetected and increasing the risk of further abuse. Objective To report an evidence-based and consensus-derived set of best practices for the radiological screening of contact children in the context of suspected child physical abuse. Evidence Review This consensus statement is supported by a systematic review of the literature and the clinical opinion of an internationally recognized group of 26 experts. The modified Delphi consensus process comprised 3 meetings of the International Consensus Group on Contact Screening in Suspected Child Physical Abuse held between February and June 2021. Findings Contacts are defined as the asymptomatic siblings, cohabiting children, or children under the same care as an index child with suspected child physical abuse. All contact children should undergo a thorough physical examination and a history elicited prior to imaging. Contact children younger than 12 months should have neuroimaging, the preferred modality for which is magnetic resonance imaging, and skeletal survey. Contact children aged 12 to 24 months should undergo skeletal survey. No routine imaging is indicated in asymptomatic children older than 24 months. Follow-up skeletal survey with limited views should be performed if abnormal or equivocal at presentation. Contacts with positive findings should be investigated as an index child. Conclusions and Relevance This Special Communication reports consensus recommendations for the radiological screening of contact children in the context of suspected child physical abuse, establishing a recognized baseline for the stringent evaluation of these at-risk children and providing clinicians with a more resilient platform from which to advocate for them.
Left Atrial Volumetric/Mechanical Coupling Index
Essayagh, Benjamin , Nistri, Stefano , Maalouf, Joseph , Rossi, Andrea , Thapa, Prabin , Michelena, Héctor I. , Enriquez‐Sarano, Maurice , Benfari, Giovanni , Michelena, Hector I , Enriquez-Sarano, Maurice , Benfari, Giovanni , Essayagh, Benjamin , Nistri, Stefano

Mayo Clinic

Circulation: Cardiovascular Imaging | March 19, 2022 | Volume: 14 | Issue: 1 | Pages: No page available

10.1161/circimaging.120.011608 | PMID 33463368 Get It

Background: Left atrial assessment is complex, particularly in heart failure with reduced ejection fraction due to interactions with functional mitral regurgitation (FMR). Pilot data suggest that left atrial volumetric/mechanical coupling index (LACI) may be useful, but large outcome data are lacking. Methods: We enrolled a comprehensively characterized cohort of patients in sinus rhythm with heart failure with reduced ejection fraction diagnosis at Mayo Clinic from 2007 to 2011. Routinely measured left atrial volume index and tissue-doppler-imaging a’ allowed LACI calculation as (left atrial volume index)/(tissue-doppler-imaging a’). Survival was the outcome measured. Results: The cohort’s 4196 patients (69 [58–77] years, ejection fraction 40 [31–45]%) had mild FMR in 1505 and moderate-severe FMR in 1068. LACI was overall 5.06 (3.50–8.10) and increased with each FMR grade (3.86 [2.94–5.29] without FMR, 5.38 [3.80–8.02] with mild, 5.45 [1.49–8.07] with moderate/severe FMR; P <0.0001). At diagnosis, higher LACI was independently determined by more severe FMR and by higher left ventricular mass index, lower ejection fraction, higher E/e’, and lower glomerular filtration rate (all P <0.0001). During follow-up 1588 (38%) patients died. In spline modeling, excess mortality appeared around LACI=6 and steeply increased thereafter (5-year survival 72±1% with LACI<6 and 49±2% with LACI ≥6, P <0.0001). Multivariable comprehensive adjustment showed LACI strong association with excess mortality (adjusted hazard ratio, 1.41 [1.23–1.61], P <0.0001 for LACI ≥6). Independent link to mortality persistent across FMR grades (adjusted hazard ratio, 1.45 [1.13–1.86], P =0.004 without FMR, 1.42 [1.16–1.77], P =0.0008 with mild FMR, and 1.38 [1.01–1.66], P =0.04 with moderate/severe FMR) without interaction ( P =0.3). LACI independent impact on outcome was incremental to that of left atrial volume index, tissue-doppler-imaging a’, or any other characteristic including the Meta-Analysis Global Group in Chronic-score (least significant P =0.02). Conclusions: In this large cohort, left atrial volumetric/mechanical coupling measured by LACI in routine practice integrates the influence of several morphological/hemodynamic determinants but displays progressive deterioration with increasing FMR severity in heart failure with reduced ejection fraction. About outcome, higher LACI is strongly, independently, and incrementally associated with excess mortality, irrespective of FMR grade and in all subsets. Hence, LACI is a novel and critical measure in heart failure with reduced ejection fraction, quantifiable in routine practice, which should be integrated in prognostication and decision-making.
The right parasternal window: when Doppler-beam alignment may be life-saving in patients with aortic valve stenosis
Benfari, Giovanni , Setti, Martina , Rossi, Andrea , Nistri, Stefano , Clavel, Marie‐Annick , Romero-Brufau, Santiago, Benfari, Giovanni , Clavel, Marie-Annick , Nistri, Stefano , Mantovani, Francesca , Romero‐Brufau, Santiago , Ribichini, Flavio Luciano

Mayo Clinic

Journal of Cardiovascular Medicine | May 13, 2020 | Volume: 21 | Issue: 10 | Pages: 831-834

10.2459/jcm.0000000000000971 | PMID 32404852 Get It

The need for multiple transducer positions, especially from right parasternal windows, is consistently mentioned in the recommendations for the accurate measurement of peak velocities across a stenotic aortic valve, but yet poorly adopted. We performed a subanalysis of the largest prospective series on the right parasternal acoustic windows in patients with aortic stenosis (330 consecutive) to calculate the degree of misalignment and estimate the potential outcome implication of this often-forgotten approach. The right parasternal view was highly feasible with an average estimated misalignment from the apical view of 14 ± 16 degree; in 10 cases, an estimated misalignment >40 degree. Right parasternal assessment (vs. apical alone) provided a significant reclassification from moderate to severe or even very-severe aortic valve stenosis. Considering a wellestablished survival benefit provided by either percutaneous or surgical valve replacement in patients with severe aortic stenosis the reclassification would result in approximately 1 life-year saved for every 30–35 patients in whom parasternal view were effectively utilized.
Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction
Benfari, Giovanni , Antoine, Clémence , Thapa, Prabin , Topilsky, Yan , Rossi, Andrea , Pislaru, Sorin V. , Enriquez‐Sarano, Maurice , Topilsky, Yan , Miller, Wayne L. , Pislaru, Sorin, Sabbah, Michael S. , Enriquez-Sarano, Maurice , Benfari, Giovanni , Topilsky, Yan , Michelena, Héctor I.

Mayo Clinic

Circulation | May 23, 2019 | Volume: 140 | Issue: 3 | Pages: 196-206

10.1161/circulationaha.118.038946 | PMID 31117814 Get It

Background: Functional tricuspid regurgitation (FTR) is common in heart failure with reduced ejection fraction and mostly consequent to pulmonary hypertension. However, the intrinsic clinical implications of FTR are not fully understood. Methods: The cohort of all Mayo Clinic patients from 2003 to 2011 diagnosed with heart failure stage B-C and ejection fraction<50%, with FTR grading and systolic pulmonary artery pressure estimation by Doppler echocardiography was identified and outcomes were analyzed. Patients with pacemakers/defibrillators, organic valve disease, or previous valve surgery were excluded. The primary outcome measure was overall mortality (censored at implantation of a defibrillator, ventricular assist device, or cardiac transplantation), adjusting for clinical and echocardiographic associates with mortality and major comorbidities. Results: Among 13 026 patients meeting inclusion criteria, FTR was detected in 88% (N=11 507: 33% trivial, 32% mild, 17% moderate, and 6% severe), aged 68±14 years, 35% women, ejection fraction 36±10%, systolic pulmonary artery pressure 41±14 mm Hg with 20% atrial fibrillation. Covariates independently associated with FTR included elevated systolic pulmonary artery pressure, older age, female sex, lower ejection fraction, mitral regurgitation, and atrial fibrillation (all P <0.0001). FTR was independently associated with more dyspnea, impaired kidney function, and lower cardiac output ( P <0.003 for all). For long-term outcome, higher FTR degree compared with trivial tricuspid regurgitation was independently associated with higher mortality (adjusted hazard ratios 1.09 [1.01-1.17] for mild FTR, 1.21 [1.11-1.33] for moderate FTR and 1.57 [1.39-1.78] for severe FTR); hence, 5-year survival was substantially lower with increasing severity of functional FTR, 68±1% for trivial FTR, 58±2% for mild FTR, 45±2% for moderate FTR, and 34±4% for severe FTR. Conclusions: In this large cohort of patients with heart failure with reduced ejection fraction, FTR was common and independently associated with pulmonary hypertension, atrial fibrillation, and more severe heart failure presentation. Long-term, higher FTR severity is associated with considerably worse survival, independently of baseline characteristics. Given these untoward outcomes associated with FTR in patients with heart failure with reduced ejection fraction, clinical trials should be directed at testing FTR treatment.
Concomitant mitral regurgitation and aortic stenosis: one step further to low-flow preserved ejection fraction aortic stenosis
Benfari, Giovanni , Clavel, Marie‐Annick , Nistri, Stefano , Maffeis, Caterina , Vassanelli, Corrado , Enriquez‐Sarano, Maurice , Rossi, Andrea , Enriquez-Sarano, Maurice , Benfari, Giovanni , Clavel, Marie-Annick , Nistri, Stefano

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | June 13, 2017 | Volume: 19 | Issue: 5 | Pages: 569-573

10.1093/ehjci/jex172 | PMID 28950322 Get It